Spontaneous hydropneumothorax: a rare presentation of pleural mesothelioma

Authors

  • Eurico Oliveira Hospital de São Teotónio – Viseu
  • Lénea Porto Hospital de São Teotónio – Viseu
  • Paula Manuel Hospital de São Teotónio – Viseu
  • Paulo Batista Hospital de São Teotónio – Viseu
  • Ana Campos Hospital de São Teotónio – Viseu
  • Simões Torres Hospital de São Teotónio – Viseu
  • João Alexandre Hospital de São Teotónio – Viseu
  • Pedro Henriques Hospital de São Teotónio – Viseu

Keywords:

Hydropneumothorax, pleura, mesothelioma, asbestosis, asbestos

Abstract

Malignant mesothelioma is an invariable lethal neoplasia that
arises from mesothelial cells from pleura, peritoneum, and
pericardium or tunica vaginalis. It represents less than 1% of all
tumors and its incidence is rising in the recent years. The typical
clinical presentation is thoracic pain, dyspnea and recurrent pleural effusion. The authors present a clinical case of an 80 year-old
man with a hydropneumothorax, which etiologic investigation
culminated with the diagnosis of malignant mesothelioma.

Downloads

Download data is not yet available.

References

Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S.

Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin Proc 1988; 63:1234.

Hodgson JT, McElvenny DM, Darnton AJ et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92:587.

Murray R. Asbestos: a chronology of its origins and health effects. B J Ind Med 1990; 47:361-365.

Hansen J, de Klerk NH, Musk AW, Hobbs MST. Environmental exposure to crocidolite and mesothelioma. Exposure-response relationships. Am J Respir Crit Care Med 1998; 157:69.

Pira E, Pelucchi C, Buffoni L et al. Cancer mortality in a cohort of asbestos textile workers. Br J Cancer 2005; 92:580.

Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18:985.

Tward JD, Wendland MM, Shrieve DC et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107:108.

Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007; 109:1432.

De Luca A, Baldi A, Esposito V et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 1997; 3:913.

McLaren BR, Haenel T, Stevenson S et al. Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas. Aust N Z J Med 2000; 30:450.

Carbone M, Pass HI. Evolving aspects of mesothelioma carcionogenesis: SV40 and genetic predisposition. J Thoracic Oncology 2006; 1:169.

Testa JR, Pass HI, Carbone M. Benign and malignant mesothelioma. In: Principles and Practice of Oncology, 6th Ed, 2001;1937.

Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S.

Hillerdal G. Malignant mesothelioma 1982: Review of 4710 published cases. Br J Dis Chest 1983; 77:321.

Bueno R, Reblando J, Glickman J et al. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2005; 78:1774.

Boutin C, Rey F, Gouvernet J et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Cancer 1993; 72:389.

Heelan RT, Rusch VW, Begg CB et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999; 172:1039.

Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002; 29:26.

Gulmez I, Kart L, Buyukoglan H et al. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J 2004; 11:287.

Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000; 37:224.

Lucas DR, Pass HI, Madan SK et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology 2003; 42:270.

Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 1996; 14:1007.

Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S.

Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38:111.

Curran D, Sahmoud T et al. Prognostic Factors in Patients with Pleural Mesothelioma: The European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998; 16:14.

Hasturk S, Hanta Ismail et al. Spontaneous hydropneumothorax: an unusual presentation of malignant pleural mesothelioma. Turkish Resp J 2002;3 (3):127-129

Additional Files

Published

2011-03-31

How to Cite

1.
Oliveira E, Porto L, Manuel P, Batista P, Campos A, Torres S, Alexandre J, Henriques P. Spontaneous hydropneumothorax: a rare presentation of pleural mesothelioma. RPMI [Internet]. 2011 Mar. 31 [cited 2024 May 21];18(1):40-4. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1302

Issue

Vol. 18 No. 1 (2011): Janeiro/ Março

Section

Case Reports

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Medicina Interna

Open Access

Most read articles by the same author(s)